Meta-Analysis
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Mar 26, 2025; 17(3): 104000
Published online Mar 26, 2025. doi: 10.4330/wjc.v17.i3.104000
Outcomes of periprocedural continuation vs interruption of oral anticoagulation in transcatheter aortic valve replacement
Aman Goyal, Aqsa Shoaib, Areeba Fareed, Sara Jawed, Muhammad Taha Khan, Najwa Salim, Ushna Zameer, Amna Siddiqui, Tanya Thakur, Samia Aziz Sulaiman
Aman Goyal, Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai 400012, Maharashtra, India
Aqsa Shoaib, Areeba Fareed, Sara Jawed, Muhammad Taha Khan, Najwa Salim, Ushna Zameer, Amna Siddiqui, Department of Internal Medicine, Karachi Medical and Dental College, Karachi 74700, Sindh, Pakistan
Tanya Thakur, Department of Internal Medicine, Government Medical College, Patiala 147001, Punjab, India
Samia Aziz Sulaiman, Department of Internal Medicine, The University of Jordan, Amman 11183, Jordan
Co-first authors: Aman Goyal and Aqsa Shoaib.
Author contributions: Goyal A and Sulaiman SA reviewed and edited the final draft; Goyal A, Shoaib A, Fareed A, Jawed S, Khan MT, Salim N, Zameer U, Siddiqui A, Thakur T, and Sulaiman SA wrote the original draft and contributed to data curation and formal analysis; All of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Samia Aziz Sulaiman, MD, Department of Internal Medicine, The University of Jordan, Water and Environment Research and Study Center, Amman 11183, Jordan. samia.sulaiman2003@gmail.com
Received: December 6, 2024
Revised: January 27, 2025
Accepted: February 21, 2025
Published online: March 26, 2025
Processing time: 105 Days and 0.7 Hours
Core Tip

Core Tip: Periprocedural continuation of oral anticoagulation (OAC) in transcatheter aortic valve replacement (TAVR) significantly reduces stroke risk (risk ratio = 0.62, P = 0.03) without increasing the incidence of major bleeding or vascular complications. Although no statistically significant difference in all-cause mortality was observed, the results suggest a favorable safety and efficacy profile for OAC continuation. These findings underscore the need for further large-scale, randomized trials to establish definitive guidelines for periprocedural anticoagulation management in patients undergoing TAVR.